Premium
Carcinogen exposure, p53 alteration, and K‐ ras mutation in synchronous multiple primary lung carcinoma
Author(s) -
Wang Xi,
Christiani David C.,
Mark Eugene J.,
Nelson Heather,
Wiencke John K.,
Gunn Laura,
Wain John C.,
Kelsey Karl T.
Publication year - 1999
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19990415)85:8<1734::aid-cncr13>3.0.co;2-1
Subject(s) - medicine , field cancerization , lung cancer , lung , adenocarcinoma , carcinoma , carcinogen , incidence (geometry) , oncology , stage (stratigraphy) , primary tumor , gastroenterology , pathology , cancer , metastasis , biology , paleontology , genetics , physics , optics
BACKGROUND Synchronous multiple primary lung tumors (SMPLT) have been estimated to occur in 1% of lung carcinoma patients. Criteria for SMPLT diagnosis include different cancer histologies, location in different lobes of the lung, or genetic discordance. Patients with SMPLT have a poor clinical prognosis with decreased 5‐year disease survival, despite diagnosis at an early stage. Field cancerization (the induction of somatic mutation in large clones of epithelial cells after carcinogen exposure) has been proposed to be an integral process involved in the development of SMPLT. Host factors also may contribute to the development of SMPLT. METHODS The authors investigated the occurrence of p53 and K‐ ras alterations in tumors from SMPLT patients and also studied the association between carcinogen exposure and polymorphic metabolic traits in SMPLT patients, comparing these patients with individuals with one primarily lung tumor. RESULTS In a case‐control study of lung carcinoma susceptibility, 6 patients were identified whose 33 multiple tumors met the criteria of SMPLT. The incidence was 3.6% (16 of 451 patients), which was higher than many previously published series. Among the multiple tumors, 73% (24 of 33 tumors) were adenocarcinomas. Patients with SMPLT smoked more (73.0 pack‐years vs. 56.2 pack‐years; P = 0.07) and longer (45.8 years vs. 37.0 years; P < 0.03) than patients with only 1 tumor. For those patients who stopped smoking, patients with SMPLT had stopped smoking more recently than those with a single primary tumor (3.4 years vs. 7.3 years; P = 0.08). A total of 39% of SMPLT tumors (13 of 33 tumors) had detectable p53 alterations; 36% had genetic changes in p53 measured by polymerase chain reaction‐single strand conformation polymorphism, and 33% showed positive immunostaining for p53 protein. This was comparable to the occurrence of p53 mutations and immunostaining in single tumor cases (30%). Age, gender, family history of cancer, and the prevalence of polymorphic metabolic traits previously associated with lung carcinoma susceptibility did not differ among SMPLT patients compared with patients with a single tumor. CONCLUSIONS The patients with SMPLT had significantly more tobacco exposure, and their tumors apparently had independently arising p53 and K‐ ras mutations, suggesting that field cancerization may be important in lung carcinogenesis. Cancer 1999;85:1734–9. © 1999 American Cancer Society.